Zynerba Pharmaceuticals
Market Cap
US$259.7m
Last Updated
2019/08/18 01:04 UTC
Data Sources
Company Financials +
Executive Summary
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.
Snowflake
Fundamentals
Flawless balance sheet with high growth potential.
Risks
- Zynerba Pharmaceuticals has significant price volatility in the past 3 months.
Share Price & News
How has Zynerba Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.2%
NasdaqGM:ZYNE
-1.8%
US Pharmaceuticals
-1.0%
US Market
1 Year Return
78.3%
NasdaqGM:ZYNE
-6.6%
US Pharmaceuticals
-0.4%
US Market
ZYNE outperformed the Pharmaceuticals industry which returned -6.6% over the past year.
ZYNE outperformed the Market in United States of America which returned -0.4% over the past year.
Share holder returns
| ZYNE | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.2% | -1.8% | -1.0% |
| 30 Day | 3.7% | -3.5% | -3.3% |
| 90 Day | -22.8% | -3.8% | 0.8% |
| 1 Year | 78.3%78.3% | -4.3%-6.6% | 1.9%-0.4% |
| 3 Year | 13.5%13.5% | 7.9%0.6% | 39.4%30.4% |
| 5 Year | n/a | 22.9%10.0% | 54.2%37.1% |
Price Volatility Vs. Market
How volatile is Zynerba Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What Kind Of Investor Owns Most Of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?1 month ago | Simply Wall St
How Much Did Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Pocket Last Year?2 months ago | Simply Wall St
The Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price Is Up 43% And Shareholders Are Holding OnValuation
Is Zynerba Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Zynerba Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
Zynerba Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Zynerba Pharmaceuticals, we can't assess if its growth is good value.
Price Based on Value of Assets
Zynerba Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Zynerba Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?
67.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Zynerba Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Zynerba Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Zynerba Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Zynerba Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
Zynerba Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Zynerba Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has Zynerba Pharmaceuticals performed over the past 5 years?
-35.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Zynerba Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Zynerba Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Zynerba Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Zynerba Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Zynerba Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Zynerba Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Zynerba Pharmaceuticals's financial position?
Financial Position Analysis
Zynerba Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Zynerba Pharmaceuticals has no long term commitments.
Debt to Equity History and Analysis
Zynerba Pharmaceuticals's level of debt (-0%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (8.2% vs -0% today).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are -4551.1x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Zynerba Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
Zynerba Pharmaceuticals has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 20% each year.
Next Steps
Dividend
What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Zynerba Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Zynerba Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Zynerba Pharmaceuticals has not reported any payouts.
Unable to verify if Zynerba Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Zynerba Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Zynerba Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
4.8yrs
Average management tenure
CEO
Armando Anido (61yo)
4.8yrs
Tenure
US$2,001,096
Compensation
Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has m ...
CEO Compensation Analysis
Armando's remuneration is higher than average for companies of similar size in United States of America.
Armando's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
4.8yrs
Average Tenure
61yo
Average Age
The tenure for the Zynerba Pharmaceuticals management team is about average.
Board Age and Tenure
4.0yrs
Average Tenure
62.5yo
Average Age
The tenure for the Zynerba Pharmaceuticals board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Shares | 5,000 |
| Max Price | US$6.43 |
Ownership Breakdown
Management Team
Armando Anido (61yo)
Chairman & CEO
- Tenure: 4.8yrs
- Compensation: $2.00m
Terri Sebree (61yo)
President
- Tenure: 4.8yrs
- Compensation: $1.28m
Will Roberts (50yo)
VP of Investor Relations & Corporate Communications
- Tenure: 2.1yrs
Jim Fickenscher (55yo)
CFO, VP of Corporate Development & Treasurer
- Tenure: 2.9yrs
- Compensation: $1.11m
Suzanne Hanlon (62yo)
Secretary
- Tenure: 4.8yrs
- Compensation: $791.52k
Joseph Palumbo
Chief Medical Officer
Board Members
Dan Kisner (72yo)
Director
- Tenure: 4.0yrs
- Compensation: $158.11k
Jacqueline French
Member of Scientific Advisory Board
Ken Moch (64yo)
Director
- Tenure: 4.0yrs
- Compensation: $160.61k
Armando Anido (61yo)
Chairman & CEO
- Tenure: 4.8yrs
- Compensation: $2.00m
Steven Siegel
Member of Scientific Advisory Board
John Messenheimer
Member of Scientific Advisory Board
Warren Cooper (66yo)
Lead Independent Director
- Tenure: 3.8yrs
- Compensation: $179.48k
Pamela Stephenson (51yo)
Director
- Tenure: 0.5yrs
Bill Federici (59yo)
Director
- Tenure: 4.0yrs
- Compensation: $166.86k
Rodney Radtke
Member of Scientific Advisory Board
Company Information
Zynerba Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zynerba Pharmaceuticals, Inc.
- Ticker: ZYNE
- Exchange: NasdaqGM
- Founded: 2007
- Industry: pharmaceuticals
- Sector: pharmaceuticals & biotech
- Market Cap: US$259.688m
- Shares outstanding: 23.19m
- Website: Click here
Number of Employees
Location
- Zynerba Pharmaceuticals, Inc.
- 80 West Lancaster Avenue
- Suite 300
- Devon
- Pennsylvania
- 19333
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZYNE | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Aug 2015 |
| 6ZY | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 2015 |
| 0M40 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Aug 2015 |
Biography
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/18 01:04 |
| End of Day Share Price | 2019/08/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.